Stoke Therapeutics, Inc.
STOK· Nasdaq
Released Nov 4, 2025, after the close
10-Q filed Nov 4, 2025, 35 days after period end · 0001193125-25-264720
| Metric | Q3 2025 | Q3 2024 | Q3 2023 | Q3 2022 |
|---|---|---|---|---|
| Revenue | $10.63M | $4.89M | $3.31M | $2.91M |
| Net Income | -$38.35M | -$26.43M | -$24.54M | -$26.11M |
| EPS Diluted |
Stoke Therapeutics, Inc. · CIK 1623526 · Engraved from SEC EDGAR
| -$0.65 |
| -$0.47 |
| -$0.55 |
| -$0.66 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.